Metabolomic-Based Stratification in Prostate Cancer

[1]  M. Loda,et al.  Metabolic Profiling in Formalin-Fixed and Paraffin-Embedded Prostate Cancer Tissues , 2017, Molecular Cancer Research.

[2]  Claudio Luchinat,et al.  KODAMA: an R package for knowledge discovery and data mining , 2016, Bioinform..

[3]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[4]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[5]  R. Langer,et al.  High‐resolution MALDI‐FT‐ICR MS imaging for the analysis of metabolites from formalin‐fixed, paraffin‐embedded clinical tissue samples , 2015, The Journal of pathology.

[6]  A. Gao,et al.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. , 2015, American journal of clinical and experimental urology.

[7]  E. Bik.  You Lose Some, You Win Some: Weight Loss Induces Microbiota and Metabolite Shifts , 2015, EBioMedicine.

[8]  P. Muti,et al.  Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. , 2015, The Biochemical journal.

[9]  Richard Ventura,et al.  Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression , 2015, EBioMedicine.

[10]  Sean C. Bendall,et al.  Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis , 2015, Cell.

[11]  K. Brindle.  Imaging metabolism with hyperpolarized (13)C-labeled cell substrates. , 2015, Journal of the American Chemical Society.

[12]  M. Loda,et al.  Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies , 2015, Molecular Cancer Research.

[13]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[14]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[15]  Eli R. Zunder,et al.  A continuous molecular roadmap to iPSC reprogramming through progression analysis of single-cell mass cytometry. , 2015, Cell stem cell.

[16]  Marius Wernig,et al.  Early reprogramming regulators identified by prospective isolation and mass cytometry , 2015, Nature.

[17]  Andrew Menzies,et al.  Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.

[18]  M. Loda,et al.  Role of diet in prostate cancer: the epigenetic link , 2014, Oncogene.

[19]  Saumyadipta Pyne,et al.  AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. , 2014, Cancer research.

[20]  Igor Jurisica,et al.  Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. , 2014, The Lancet. Oncology.

[21]  Peter Kraft,et al.  A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer , 2014, Nature Genetics.

[22]  C. Nelson,et al.  The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer , 2014, Oncotarget.

[23]  Sadhna Verma,et al.  Anatomic Imaging of the Prostate , 2014, BioMed research international.

[24]  Jie Lu,et al.  c-Myc Programs Fatty Acid Metabolism and Dictates Acetyl-CoA Abundance and Fate* , 2014, The Journal of Biological Chemistry.

[25]  M. Loda,et al.  Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error , 2014, British Journal of Cancer.

[26]  Chris Sander,et al.  Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.

[27]  R. Tibshirani,et al.  Alteration of the lipid profile in lymphomas induced by MYC overexpression , 2014, Proceedings of the National Academy of Sciences.

[28]  D. Valentine,et al.  Unprecedented Ultrahigh Resolution FT-ICR Mass Spectrometry and Parts-Per-Billion Mass Accuracy Enable Direct Characterization of Nickel and Vanadyl Porphyrins in Petroleum from Natural Seeps , 2014 .

[29]  Jennifer R. Rider,et al.  SPINK1 Protein Expression and Prostate Cancer Progression , 2014, Clinical Cancer Research.

[30]  Claudio Luchinat,et al.  Knowledge discovery by accuracy maximization , 2014, Proceedings of the National Academy of Sciences.

[31]  M. Loda,et al.  De novo fatty acid synthesis at the mitotic exit is required to complete cellular division , 2014, Cell cycle.

[32]  Mikko I. Kettunen,et al.  Magnetic resonance imaging of tumor glycolysis using hyperpolarized 13C-labeled glucose , 2013, Nature Medicine.

[33]  Kurt Zatloukal,et al.  Effects of intra- and post-operative ischemia on the metabolic profile of clinical liver tissue specimens monitored by NMR. , 2013, Journal of proteome research.

[34]  M. Loda,et al.  The fat side of prostate cancer. , 2013, Biochimica et biophysica acta.

[35]  P. Austin,et al.  Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  E. Mostaghel.  Steroid hormone synthetic pathways in prostate cancer , 2013, Translational andrology and urology.

[37]  Jennifer R. Rider,et al.  Gleason grade progression is uncommon. , 2013, Cancer research.

[38]  P. Larson,et al.  Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.

[39]  M. Rubin,et al.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.

[40]  Anastasia K Yocum,et al.  The role of sarcosine metabolism in prostate cancer progression. , 2013, Neoplasia.

[41]  Arend Heerschap,et al.  Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer – investigation of a correlation with Gleason score , 2013, NMR in biomedicine.

[42]  T. Bathen,et al.  Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness , 2013, PloS one.

[43]  E. Petricoin,et al.  The role of proteomics in prostate cancer research: biomarker discovery and validation. , 2013, Clinical biochemistry.

[44]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[45]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[46]  Pier Paolo Pandolfi,et al.  Cancer metabolism: fatty acid oxidation in the limelight , 2013, Nature Reviews Cancer.

[47]  Charles Pound,et al.  Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics , 2012, PloS one.

[48]  A. Wolk,et al.  Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  Jennifer R. Rider,et al.  The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[50]  Wei Liu,et al.  Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC , 2012, Proceedings of the National Academy of Sciences.

[51]  J. Asara,et al.  A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue , 2012, Nature Protocols.

[52]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[53]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[54]  Monish Aron,et al.  3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. , 2012, The Journal of urology.

[55]  T. Fan,et al.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. , 2012, Cell metabolism.

[56]  Markus Perola,et al.  Genome-wide association study identifies multiple loci influencing human serum metabolite levels , 2012, Nature Genetics.

[57]  Ke Sheng,et al.  Correlation of Gleason Scores with Diffusion-Weighted Imaging Findings of Prostate Cancer , 2011, Advances in urology.

[58]  Christina Bougatsos,et al.  Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[59]  J. Asara,et al.  Metabolomic Profiling from Formalin-Fixed, Paraffin-Embedded Tumor Tissue Using Targeted LC/MS/MS: Application in Sarcoma , 2011, PloS one.

[60]  Nallasivam Palanisamy,et al.  Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.

[61]  J. Kurhanewicz,et al.  Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage – impact of tissue environment , 2011, NMR in biomedicine.

[62]  Tamra E. Meyer,et al.  A reproducible and high-throughput HPLC/MS method to separate sarcosine from α- and β-alanine and to quantify sarcosine in human serum and urine. , 2011, Analytical chemistry.

[63]  F. Gallagher,et al.  Hyperpolarized [1-13C]-Ascorbic and Dehydroascorbic Acid: Vitamin C as a Probe for Imaging Redox Status in Vivo , 2011, Journal of the American Chemical Society.

[64]  M. Loda,et al.  Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  T. Golub,et al.  mRNA expression signature of Gleason grade predicts lethal prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  S. Dhanasekaran,et al.  Characterization of KRAS rearrangements in metastatic prostate cancer. , 2011, Cancer discovery.

[67]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[68]  Francesca Demichelis,et al.  Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. , 2011, Genome research.

[69]  Gary Siuzdak,et al.  Nanostructure-initiator mass spectrometry metabolite analysis and imaging. , 2011, Analytical chemistry.

[70]  Pär Stattin,et al.  Metabolomic Characterization of Human Prostate Cancer Bone Metastases Reveals Increased Levels of Cholesterol , 2010, PloS one.

[71]  F. Gallagher,et al.  Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate , 2010, British Journal of Cancer.

[72]  Fionnuala Morrish,et al.  Myc-dependent Mitochondrial Generation of Acetyl-CoA Contributes to Fatty Acid Biosynthesis and Histone Acetylation during Cell Cycle Entry* , 2010, The Journal of Biological Chemistry.

[73]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[74]  M. Loda,et al.  New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK , 2010, Clinical Cancer Research.

[75]  C. Bieberich,et al.  MYC and Prostate Cancer. , 2010, Genes & cancer.

[76]  Elaine Holmes,et al.  High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues , 2010, Nature Protocols.

[77]  M. Loda,et al.  Fatty acid synthase as a potential therapeutic target in cancer. , 2010, Future oncology.

[78]  G. Castellano,et al.  Tumor and Stem Cell Biology Cancer Research Activation of Phosphatidylcholine Cycle Enzymes in Human Epithelial Ovarian Cancer Cells , 2010 .

[79]  Leo L. Cheng,et al.  Metabolomic Imaging for Human Prostate Cancer Detection , 2010, Science Translational Medicine.

[80]  S. Varambally,et al.  Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer , 2009, Science.

[81]  Sarah E Bohndiek,et al.  Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors , 2009, Proceedings of the National Academy of Sciences.

[82]  A. Ramírez de Molina,et al.  Differential Role of Human Choline Kinase α and β Enzymes in Lipid Metabolism: Implications in Cancer Onset and Treatment , 2009, PloS one.

[83]  W. Hahn,et al.  Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. , 2009, Journal of the National Cancer Institute.

[84]  W. Gerald,et al.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.

[85]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[86]  Anthony Mancuso,et al.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.

[87]  M. Stampfer,et al.  Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. , 2008, The Lancet. Oncology.

[88]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[89]  P. Carroll,et al.  Quantification of choline‐ and ethanolamine‐containing metabolites in human prostate tissues using 1H HR‐MAS total correlation spectroscopy , 2008, Magnetic resonance in medicine.

[90]  Pernille R. Jensen,et al.  Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate , 2008, Nature.

[91]  Holly T. Sullivan,et al.  The Prostate 68 : 620 ^ 628 ( 2008 ) TheMetabolitesCitrate , Myo-Inositol , and Spermine Are PotentialAge-IndependentMarkers of Prostate Cancer inHumanExpressed Prostatic Secretions , 2008 .

[92]  Jan Wolber,et al.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy , 2007, Nature Medicine.

[93]  Yan Liu,et al.  Risk factors for prostate cancer incidence and progression in the health professionals follow‐up study , 2007, International journal of cancer.

[94]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[95]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[96]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[97]  E. Marshall.  Canadian Group Claims 'Unique' Database , 2007, Science.

[98]  R. Shaw,et al.  Glucose metabolism and cancer. , 2006, Current opinion in cell biology.

[99]  Y. Liu,et al.  Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.

[100]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[101]  Oliver Fiehn,et al.  Metabolomic database annotations via query of elemental compositions: Mass accuracy is insufficient even at less than 1 ppm , 2006, BMC Bioinformatics.

[102]  C. Wild.  Complementing the Genome with an “Exposome”: The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology , 2005, Cancer Epidemiology Biomarkers & Prevention.

[103]  David Gallego-Ortega,et al.  Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. , 2005, Cancer research.

[104]  W. Isaacs,et al.  Peroxisomal branched chain fatty acid β‐oxidation pathway is upregulated in prostate cancer , 2005, The Prostate.

[105]  W. Dunn,et al.  Measuring the metabolome: current analytical technologies. , 2005, The Analyst.

[106]  L. Sillerud,et al.  A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma. , 2005, The Journal of urology.

[107]  E. Lander,et al.  Finishing the euchromatic sequence of the human genome , 2004 .

[108]  R. Cooks,et al.  Mass Spectrometry Sampling Under Ambient Conditions with Desorption Electrospray Ionization , 2004, Science.

[109]  P. Hammerman,et al.  Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[110]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[111]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[112]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.

[113]  Massimo Loda,et al.  Fatty acid synthase: A metabolic oncogene in prostate cancer? , 2004, Journal of cellular biochemistry.

[114]  M. Freeman,et al.  Cholesterol and prostate cancer , 2004, Journal of cellular biochemistry.

[115]  P. Carroll,et al.  Proton HR‐MAS spectroscopy and quantitative pathologic analysis of MRI/3D‐MRSI‐targeted postsurgical prostate tissues , 2003, Magnetic resonance in medicine.

[116]  P. Hammerman,et al.  Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival , 2003, Molecular and Cellular Biology.

[117]  C. Thompson,et al.  Activated Akt promotes increased resting T cell size, CD28‐independent T cell growth, and development of autoimmunity and lymphoma , 2003, European journal of immunology.

[118]  P. Febbo,et al.  Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. , 2003, Molecular cancer research : MCR.

[119]  E. Williams,et al.  Expression and localization of GLUT1 and GLUT12 in prostate carcinoma , 2003, Cancer.

[120]  R. Rosell,et al.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.

[121]  C. Thompson,et al.  Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. , 2002, Molecular biology of the cell.

[122]  Jose M. Silva,et al.  Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy , 2002, Oncogene.

[123]  Rajiv Dhir,et al.  Gene expression analysis of prostate cancers , 2002, Molecular carcinogenesis.

[124]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[125]  E. Yeung,et al.  Direct analysis of single rat peritoneal mast cells with laser vaporization/ionization mass spectrometry. , 1998, Analytical chemistry.

[126]  S. Schnitt,et al.  p53 antigen loss in stored paraffin slides. , 1995, The New England journal of medicine.

[127]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[128]  J Kurhanewicz,et al.  Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. , 1995, Urology.

[129]  A W Partin,et al.  OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. , 1995, Urology.

[130]  J. Bock,et al.  Metabolic profiling of amniotic fluid by proton nuclear magnetic resonance spectroscopy: correlation with fetal maturation and other clinical variables. , 1994, Clinical chemistry.

[131]  R. Franklin,et al.  Citrate modulation of high-affinity aspartate transport in prostate epithelial cells. , 1993, Cellular and molecular biology.

[132]  R. Franklin,et al.  High‐affinity L‐aspartate transporter in prostate epithelial cells that is regulated by testosterone , 1993, The Prostate.

[133]  O. Warburg.  On respiratory impairment in cancer cells. , 1956, Science.